| Market Cap | 242.45M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -7.57M | Forward P/E | 6.33 | EPS next Y | - | 50D Avg Chg | -8.00% |
| Sales | 61.64M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -2.00% |
| Dividend | N/A | Price/Book | 4.22 | EPS next 5Y | - | 52W High Chg | -28.00% |
| Recommedations | 1.80 | Quick Ratio | 3.51 | Shares Outstanding | 80.84M | 52W Low Chg | 50.00% |
| Insider Own | - | ROA | -4.04% | Shares Float | 30.66M | Beta | 0.66 |
| Inst Own | 0.17% | ROE | -14.28% | Shares Shorted/Prior | 79.10K/76.87K | Price | 2.85 |
| Gross Margin | 9.12% | Profit Margin | -12.28% | Avg. Volume | 11,617 | Target Price | 7.40 |
| Oper. Margin | -57.22% | Earnings Date | May 14 | Volume | 27,237 | Change | -4.68% |
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
| HC Wainwright & Co. | Buy | May 15, 24 |
| HC Wainwright & Co. | Buy | Apr 11, 24 |
| HC Wainwright & Co. | Buy | Mar 22, 24 |
| HC Wainwright & Co. | Buy | Nov 15, 23 |
| HC Wainwright & Co. | Buy | Sep 18, 23 |
| HC Wainwright & Co. | Buy | Jun 16, 23 |
| HC Wainwright & Co. | Buy | Mar 24, 23 |
| SVB Leerink | Outperform | Nov 15, 22 |
| Citigroup | Buy | Sep 16, 22 |